AstraZeneca expands anti-infectives portfolio with up to $505 million buy of France’s Novexel and makes deal with Forest; MedImmune recall, motavizumab update
Article | 24 December 2009
Anglo-Swedish drug major AstraZeneca revealed yesterday afternoon that it is to acquire Novexel, a French speciality pharmaceutical company focused on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
